EN DE
Watch Candel Therapeutics Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Candel Therapeutics Inc (CADL) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of Candel Therapeutics Inc stock $2.67, price $6.20, that is 56.9% below the price, quality 33 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US1374041093

CT Candel Therapeutics Inc logo Thin data Nov 15, 2026

Candel Therapeutics Inc

CADL · US

Far too expensive (fair value 57% below the price) and weak company, but rising price: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Moderate debt 
Insiders sold $3.6M (6M) 
Fair value $2.67 · Strongly overvalued 
Quality 33/100 
Weak Growth (revenue 3y −37.2 %/yr in USD) 
Negative free cash flow 
Trails peers (2/8) 
Narrow moat 8/100 · thin data
Thin data 
Estimate
Watch Candel Therapeutics Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$14.00 $0.6751 Fair Value $2.67 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.

How to read this chart

60‑month range $0.6751 – $14.00 · fair‑value band $2.01 – $3.34 · the $6.20 price screens above the $2.67 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.

Follow Candel Therapeutics in your weekly email

Every Wednesday you see whether Candel Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients.

Show moreShow less

It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma.

In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors.

The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Stock analysis

Candel Therapeutics Inc (CADL) currently trades at $6.20, while our estimate is $2.67, 57% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $2.01 (bear) to $3.34 (bull), the price of $6.20 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Candel Therapeutics Inc reported revenue of $0 in FY2025 versus $125K in FY2021. Reported net income was −$38.2M in FY2025.

Key figures

Market cap $460M Small · EPS (TTM) $−1.53 · Return on equity −93.7% · Return on assets (EBIT) −47.2% (5-year average) · Revenue (TTM) $31.0K · Free cash flow −$38.9M · Net cash $118M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 55% below its 52-week high and 40% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −57%, CADL screens richer than that median.

Fair Value

Bear $2.01 Fair Value $2.67 Bull $3.34
Price $6.20 · Downside -56.9%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 33/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 75
Are margins and returns getting better?
Cashflow 34
Do the profits arrive as real cash?
Financial strength 51
Debt, balance sheet and risk of trouble
Investment 51
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 32
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 41
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 3 officers or directors sold shares worth $3.6M and none bought.

  • SalePaul Peter TakChief Executive Officer, Director280,245 shares at $11.28$3.2MSep 11, 202610b5-1 plan
  • SaleSeshu TyagarajanChief Technology Officer2× since Jun 29, 2026: 14,000 shares, avg. $11.01$154,140Aug 17, 202610b5-1 plan
  • SaleFrancesca BaroneChief Scientific Officer23,447 shares at $10.06$235,877Jun 29, 202610b5-1 plan
  • BuyPaul B ManningDirector550,458 shares at $5.45$3.0MFeb 23, 2026

Plus one other filing such as a grant, option exercise or tax withholding. It is not a market purchase or sale.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 13, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−75.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−37.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−7,229.6% (2019) → −123,841.9% (2023)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

CADL screens overvalued: fair value 57% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Candel Therapeutics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 853 stocks

Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 33 · Below median
Fair Value upside −56.9% · Bottom 25%
Profitability
Return on assets −30.5% · Below median
Operating margin (12 months) 0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median
Balance sheet
Debt / equity 0.91× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 8.85× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)55 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $955.47 $1,275 +33% vs CADL
Genmab A/S GMAB kr 3,448 kr 3,917 +14% vs CADL
Vertex Pharmaceuticals Incorporated VRTX $538.60 $592.46 +10% vs CADL
Samsung Biologics Co 207940 1,411,000 KRW 1,552,100 KRW +10% vs CADL
argenx SE ARGX $960.04 $908.40 −5% vs CADL
CSL Limited CSL A$202.92 A$183.54 −10% vs CADL
Moderna, Inc MRNA $223.37 $139.99 −37% vs CADL
BeOne Medicines AG 6160 HK$249.80 HK$152.80 −39% vs CADL
Celltrion, Inc 068270 214,000 KRW 74,945 KRW −65% vs CADL
Royalty Pharma plc RPRX $69.31 $19.01 −73% vs CADL

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Candel Therapeutics Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Candel Therapeutics Inc Fair Value". https://www.fairvalue-calculator.com/stock/CADL

Frequently asked questions

Is Candel Therapeutics Inc (CADL) overvalued or undervalued?
As of Nov 15, 2026, our estimate of fair value is $2.67 versus a price of $6.20, about 57% lower (overvalued).
What is the fair value of CADL?
Our estimate for Candel Therapeutics Inc is $2.67 (as of Nov 15, 2026), built from audited fundamentals. The current price: $6.20.
What is the quality score of CADL?
Candel Therapeutics Inc has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Candel Therapeutics Inc (CADL)?
Our calculated price target is the estimate of $2.67 (as of Nov 15, 2026). Cautious scenario $2.01, optimistic scenario $3.34. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Candel Therapeutics Inc stock forecast for 2026?
Our estimate puts fair value at $2.67, about 57% lower versus a price of $6.20 (overvalued). Cautious scenario $2.01, optimistic scenario $3.34. The calculation is refreshed regularly with new filings.
What is the revenue of Candel Therapeutics Inc (CADL)?
Candel Therapeutics Inc reported trailing-twelve-month revenue of about $31.0K (latest available figure, as of Nov 15, 2026).
What is the intrinsic value of Candel Therapeutics Inc (CADL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Candel Therapeutics Inc it is $2.67 per share (as of Nov 15, 2026), against a price of $6.20.
Is Candel Therapeutics Inc stock overvalued or undervalued in 2026?
As of Nov 15, 2026, CADL trades above its calculated fair value: price $6.20, fair value $2.67, a gap of about −57% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CADL?
No. The price is what the market pays today ($6.20); the fair value is what the company's own numbers justify ($2.67). For Candel Therapeutics Inc the two are $3.53 per share apart. That gap is exactly why we show both numbers side by side.
How much is Candel Therapeutics Inc worth?
The market values Candel Therapeutics Inc at about $460M (market capitalisation, as of Nov 15, 2026). Per share that is $6.20; our models calculate a fair value of $2.67 per share.
What do the bullish and bearish scenarios say about CADL?
Our models span a range for Candel Therapeutics Inc: cautious scenario $2.01, base $2.67, optimistic $3.34 per share (as of Nov 15, 2026, price $6.20). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Candel Therapeutics Inc (CADL)?
Balance-sheet figures for Candel Therapeutics Inc (as of Nov 15, 2026): return on equity −93.7%, debt of 0.91 per unit of equity. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
How far is CADL from its 52-week high?
Candel Therapeutics Inc trades at $6.20, about 55% below its 52-week high of $13.75 and 40% above the low of $4.42 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of $2.67 is for.
Which stocks are comparable to Candel Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Candel Therapeutics Inc stock attractive at the current price?
The data as of Nov 15, 2026: price $6.20, calculated fair value $2.67 (−57%), Quality Score 33/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1% above its aggregate fair value. Candel Therapeutics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Candel Therapeutics Inc (CADL)?
The closing price on Nov 13, 2026 was $6.20. Our estimate is $2.67, about 57% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Candel Therapeutics Inc right now?
The price sits above even our optimistic bull case ($3.34). The favourable scenario is already priced in. Weak quality (33/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Candel Therapeutics Inc

How large is the market capitalisation of Candel Therapeutics Inc (CADL)?
The market capitalisation of Candel Therapeutics Inc is $460M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Candel Therapeutics Inc (CADL)?
Earnings per share at Candel Therapeutics Inc are $−1.53. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Candel Therapeutics Inc (CADL)?
The return on equity (ROE) of Candel Therapeutics Inc is −93.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Candel Therapeutics Inc (CADL)?
On an EBIT basis the return on assets of Candel Therapeutics Inc is −47.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Candel Therapeutics Inc (CADL) generate?
The free cash flow of Candel Therapeutics Inc is −$38.9M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Candel Therapeutics Inc (CADL) hold?
Candel Therapeutics Inc holds more cash than debt, $118M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Candel Therapeutics Inc in the live analysis

One click puts Candel Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.